Last reviewed · How we verify
Vincristine, Carboplatin
Vincristine is a vinca alkaloid that inhibits microtubule formation in the mitotic spindle, resulting in cell cycle arrest at the metaphase.
Vincristine is a vinca alkaloid that inhibits microtubule formation in the mitotic spindle, resulting in cell cycle arrest at the metaphase. Used for Acute lymphoblastic leukemia, Hodgkin's lymphoma, Non-Hodgkin's lymphoma.
At a glance
| Generic name | Vincristine, Carboplatin |
|---|---|
| Also known as | Oncovin + Paraplatin |
| Sponsor | St. Jude Children's Research Hospital |
| Drug class | Vinca alkaloid and platinum-based chemotherapy |
| Target | Microtubules |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This leads to apoptosis in rapidly dividing cancer cells. Carboplatin, a platinum-based chemotherapy drug, works by cross-linking DNA, thereby inhibiting DNA replication and transcription, and inducing apoptosis in cancer cells.
Approved indications
- Acute lymphoblastic leukemia
- Hodgkin's lymphoma
- Non-Hodgkin's lymphoma
- Ovarian cancer
- Small cell lung cancer
- Testicular cancer
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Nausea and vomiting
- Diarrhea
- Fatigue
Key clinical trials
- A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma (PHASE3)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma (PHASE3)
- Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (PHASE2)
- Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion (EARLY_PHASE1)
- Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT) (PHASE1)
- A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) (PHASE3)
- Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vincristine, Carboplatin CI brief — competitive landscape report
- Vincristine, Carboplatin updates RSS · CI watch RSS
- St. Jude Children's Research Hospital portfolio CI